Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Effect of COVID-19 on hereditary angioedema activity and quality of life.

Tytuł:
Effect of COVID-19 on hereditary angioedema activity and quality of life.
Autorzy:
Can Bostan O
Tuncay G
Damadoglu E
Karakaya G
Kalyoncu AF
Źródło:
Allergy and asthma proceedings [Allergy Asthma Proc] 2021 Sep 01; Vol. 42 (5), pp. 403-408.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: Providence, R.I. : OceanSide Publications, c1996-
MeSH Terms:
Disease Progression*
Quality of Life*/psychology
Severity of Illness Index*
Angioedemas, Hereditary/*complications
COVID-19/*complications
Acute Disease ; Adult ; Aged ; Aged, 80 and over ; Angioedemas, Hereditary/diagnosis ; Angioedemas, Hereditary/physiopathology ; Angioedemas, Hereditary/psychology ; COVID-19/diagnosis ; COVID-19/physiopathology ; COVID-19/psychology ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged
References:
Allergy Asthma Proc. 2012 Nov-Dec;33 Suppl 1:S145-56. (PMID: 23394603)
Clin Sci (Lond). 2020 Mar 13;134(5):543-545. (PMID: 32167153)
Allergy Asthma Proc. 2020 Nov 1;41(Suppl 1):S08-S13. (PMID: 33109318)
J Allergy Clin Immunol Pract. 2021 Jan;9(1):132-150.e3. (PMID: 32898710)
Clin Exp Allergy. 2021 Jul;51(7):947-950. (PMID: 33772888)
EClinicalMedicine. 2020 Aug;25:100463. (PMID: 32838236)
Allergy. 2018 Aug;73(8):1575-1596. (PMID: 29318628)
Allergy. 2021 Aug;76(8):2535-2543. (PMID: 33650198)
Allergy. 2013 Sep;68(9):1185-92. (PMID: 23919330)
Allergy Asthma Clin Immunol. 2021 Apr 19;17(1):40. (PMID: 33875020)
J Allergy Clin Immunol Pract. 2021 Jan;9(1):508-510. (PMID: 33271349)
Allergy Asthma Proc. 2019 Nov 1;40(6):441-445. (PMID: 31690390)
Allergy. 2012 Oct;67(10):1289-98. (PMID: 22913638)
J Allergy Clin Immunol. 2004 Sep;114(3 Suppl):S51-131. (PMID: 15356535)
Cell. 2020 Apr 16;181(2):271-280.e8. (PMID: 32142651)
Entry Date(s):
Date Created: 20210903 Date Completed: 20210920 Latest Revision: 20220104
Update Code:
20240105
PubMed Central ID:
PMC8677498
DOI:
10.2500/aap.2021.42.210066
PMID:
34474710
Czasopismo naukowe
Background: The demonstration that severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) enters the cell via the angiotensin-converting enzyme 2 receptor has raised concerns that, in hereditary angioedema (HAE), a disease characterized by bradykinin-mediated angioedema attacks, coronavirus disease 2019 (COVID-19) may trigger angioedema attacks, increase the frequency and/or severity of attacks, or cause more severe symptoms of COVID-19. Objective: The objective was to evaluate the severity of COVID-19 in patients with HAE, the course of HAE attacks, angioedema activity, and the quality-of-life scores during COVID-19 pandemic. Methods: Patients diagnosed with HAE for at least 6 months were included in the study. The 7-day Angioedema Activity Score and the Angioedema Quality of Life (AE-QoL) Questionnaire were first completed at the onset of the pandemic between March 12 and June 1, 2020, then during SARS-CoV-2 infection, and in the third month after recovering from COVID-19. Results: Ten of 67 patients with HAE (14.9%) were diagnosed with COVID-19. The median (interquartile range) age of the 10 patients diagnosed with COVID-19 was 35.5 years (28.0-55.0 years). Six of the 10 patients (60%) were women. During COVID-19, five of the 10 patients (50%) had no angioedema attack. Two patients with severe HAE experienced a significant increase in angioedema activity during COVID-19 compared with their basal activity scores. The remaining three patients had a similar or lower attack frequency than their basal level. Four (40%) of the 10 patients had a relative increase in their attacks during the convalescence period. There was no statistically significant difference among pre-COVID-19, during COVID-19 and post-COVID-19 periods in function, mood, fear and/or shame, nutrition, and total scores of the AE-QoL Questionnaire although the fear dimension was relatively more affected (p = 0.06). Conclusion: Although the sample size was small, analysis of our data supported that the symptoms of COVID-19 were not more severe in HAE. Also, there was no significant difference in the AE-QoL Questionnaire scores, the frequency, and severity of angioedema attacks during the course of COVID-19 in the patients with HAE.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies